Compare CAC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | FTRE |
|---|---|---|
| Founded | 1875 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.1M | 1.3B |
| IPO Year | 1996 | 2023 |
| Metric | CAC | FTRE |
|---|---|---|
| Price | $50.09 | $15.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $47.00 | $14.06 |
| AVG Volume (30 Days) | 77.4K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | $41,739,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | $3.09 |
| P/E Ratio | $38.62 | ★ N/A |
| Revenue Growth | ★ 16.96 | 1.00 |
| 52 Week Low | $35.00 | $3.97 |
| 52 Week High | $53.71 | $18.67 |
| Indicator | CAC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 69.44 |
| Support Level | $47.12 | $9.01 |
| Resistance Level | $51.57 | $16.20 |
| Average True Range (ATR) | 1.07 | 0.72 |
| MACD | 0.21 | -0.05 |
| Stochastic Oscillator | 77.44 | 87.01 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.